Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2025-02-24 00:00:00 ET · period of report 2025-02-21 · accession 0001628280-25-007532 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-24 | 2025-02-21 | SUPN | Rubin Jonathan | SVP, Chief Medical Off | M - OptEx | $0.00 | +1,875 | 8,780 | +27% | $0 |
| D | 2025-02-24 | 2025-02-21 | SUPN | Rubin Jonathan | SVP, Chief Medical Off | S - Sale+OE | $39.15 | -927 | 7,853 | -11% | -$36.3K |
| DM | 2025-02-24 | 2025-02-22+ | SUPN | Rubin Jonathan | SVP, Chief Medical Off | A - Grant | $0.00 | +3,250 | 8,603 | +61% | $0 |
| D | 2025-02-24 | 2025-02-21 | SUPN | Rubin Jonathan | SVP, Chief Medical Off | M - OptEx | $0.00 | -1,875 | 0 | -100% | $0 |
| DM | 2025-02-24 | 2025-02-22+ | SUPN | Rubin Jonathan | SVP, Chief Medical Off | D - Sale to Iss | $0.00 | -3,250 | 2,500 | -57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-21 | M | A | 1,875 | $0.00 | 8,780 | D | — | — | (F1) Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. |
| 2 | Common | Common Stock | 2025-02-21 | S | D | 927 | $39.15 | 7,853 | D | — | — | (F2) Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| 3 | Common | Common Stock | 2025-02-23 | A | A | 1,250 | $0.00 | 11,103 | D | — | — | |
| 4 | Common | Common Stock | 2025-02-22 | A | A | 1,250 | $0.00 | 9,853 | D | — | — | |
| 5 | Common | Common Stock | 2025-02-22 | A | A | 750 | $0.00 | 8,603 | D | — | — | |
| 6 | Derivative | Performance Share Units | 2025-02-21 | M | D | 1,875 | $0.00 | 0 | D | $0.00 · — to — | 1,875 Common Stock | (F3) On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. |
| 7 | Derivative | Restricted Stock Unit | 2025-02-22 | D | D | 750 | $0.00 | 750 | D | — · — to — | 750 Common Stock | (F4) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F5) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. |
| 8 | Derivative | Restricted Stock Unit | 2025-02-22 | D | D | 1,250 | $0.00 | 3,750 | D | — · — to — | 1,250 Common Stock | (F4) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F6) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. |
| 9 | Derivative | Restricted Stock Unit | 2025-02-23 | D | D | 1,250 | $0.00 | 2,500 | D | — · — to — | 1,250 Common Stock | (F4) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F7) These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. |